glp1Not FDA-approvedPrescription only (US)Not yet FDA- or EMA-approved; available only through the clinical trials cited here as of this writingMarketed availability, once approved, is expected to be prescription-only, consistent with other GLP-1 receptor agonists
OrforglipronBenefits, Dosage & Interactions
Orforglipron is an investigational non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed for the treatment of obesity and type 2 diabetes. Research on Orforglipron focuses on weight loss and blood sugar control. It is typically taken in the morning. The reported plasma half-life is about 29 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 3 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials published.
Plasma half-life
29–49 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Phase 2 obesity trial tested 12, 24, and 36 mg once daily after titration; the phase 3 obesity and diabetes trials used similar once-daily titrated doses up to 36 mg[1][2][3]
- Frequency
- Once daily, taken without the food and water timing restrictions required by peptide oral GLP-1 drugs[1][2][3]
Reported for Orforglipron in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Orforglipron entry is written from. Each number matches an inline marker above.
- [1]Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityWharton S, Blevins T, Connery L, et al. · The New England Journal of Medicine · 2023 · Peer-reviewed · PMID 37351564
- [2]Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentWharton S, et al. · The New England Journal of Medicine · 2025 · Peer-reviewed · PMID 40960239
- [3]Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 DiabetesRosenstock J, et al. · The New England Journal of Medicine · 2025 · Peer-reviewed · PMID 40544435
- [4]The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronSloop KW, Emmerson PJ, Statnick MA, Willard FS · Science Translational Medicine · 2024 · Peer-reviewed · PMID 39693407
How to track Orforglipron doses
Orforglipron is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Orforglipron is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency (typical timing: morning). Cycled protocols get a start and end date so the history stays accurate when Orforglipron comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 29 h, effects and timing shifts show up over days rather than instantly. Review Orforglipron alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Orforglipron dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Orforglipron studied for?
What is Orforglipron?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Orforglipron is an investigational non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed for the treatment of obesity and type 2 diabetes. Unlike many other GLP-1 receptor agonists, orforglipron is administered orally, offering a potential convenience advantage over injectable forms. It is designed to mimic the action of naturally occurring GLP-1, a hormone that plays a crucial role in regulating blood glucose and appetite.
GLP-1 receptor agonists work by activating GLP-1 receptors in various tissues, including the pancreas, brain, and gastrointestinal tract. This activation leads to several physiological responses that can contribute to weight loss and improved glycemic control. Clinical trials are currently evaluating its efficacy and safety profile across different populations (clinical trial registries, manufacturer press releases).
As an investigational compound, orforglipron has not yet received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general medical use. Its availability and recommended use will depend on successful completion of clinical development and subsequent regulatory review.
What does the research say about Orforglipron?
Tap a section to expand.
Orforglipron functions as an agonist at the glucagon-like peptide-1 (GLP-1) receptor. Upon binding to and activating these receptors, it triggers a cascade of intracellular signaling events that lead to several physiological effects. These effects collectively contribute to its potential therapeutic actions in metabolic disorders.
Key mechanisms include:
* **Glucose-dependent insulin secretion:** Orforglipron stimulates the pancreas to release insulin in response to elevated blood glucose levels. This action is glucose-dependent, meaning it is less likely to cause hypoglycemia (low blood sugar) when glucose levels are normal (NIH NIDDK, PubChem).
* **Suppression of glucagon secretion:** It also reduces the secretion of glucagon, another pancreatic hormone that raises blood glucose. By decreasing glucagon, orforglipron helps to further lower blood sugar levels (NIH NIDDK).
* **Delay of gastric emptying:** Orforglipron slows down the rate at which food leaves the stomach. This can lead to a feeling of fullness and contribute to reduced food intake (PubMed Central review articles).
* **Central effects on appetite and satiety:** GLP-1 receptors are present in the brain, particularly in areas involved in appetite regulation. Activation of these receptors by orforglipron can lead to a reduction in appetite and an increase in feelings of satiety, thereby decreasing overall caloric intake and promoting weight loss (review articles via PubMed).
As a non-peptide molecule, orforglipron has a different chemical structure compared to naturally occurring GLP-1 and peptide-based GLP-1 receptor agonists, allowing for oral bioavailability. Its prolonged half-life, reported to be approximately 29 hours (manufacturer data via clinical trial reports), supports once-daily dosing.
Source for this section: Sources for How does Orforglipron work?: Jumps to this entry in the sources and references list at the end of the page.
The primary potential benefits of orforglipron, as evaluated in ongoing clinical trials, are related to weight management and glucose control. These benefits align with the known actions of GLP-1 receptor agonists.
* **Weight Loss:** Clinical studies have shown that orforglipron can lead to significant reductions in body weight in individuals with obesity or overweight. This effect is attributed to its impact on appetite regulation, increased satiety, and delayed gastric emptying (clinical trial data presented at scientific meetings, manufacturer press releases).
* **Improved Glycemic Control:** For individuals with type 2 diabetes, orforglipron is expected to improve blood glucose levels. This occurs through enhanced glucose-dependent insulin secretion, reduced glucagon secretion, and potentially improved insulin sensitivity (PubChem, NIH NIDDK).
* **Oral Administration:** A key advantage of orforglipron is its oral formulation. This may offer greater convenience and improved patient adherence compared to injectable GLP-1 receptor agonists, potentially expanding access to this class of medication (manufacturer statements).
* **Cardiovascular Benefits (Potential):** While not yet fully established for orforglipron specifically, some GLP-1 receptor agonists have demonstrated cardiovascular benefits such as reduced risk of major adverse cardiovascular events in individuals with established cardiovascular disease (AHA/ACC guidelines regarding GLP-1RAs). Ongoing trials will determine if orforglipron shares similar cardiovascular protective effects.
It is important to note that these benefits are under investigation and are based on preliminary data and expectations derived from the drug class. Final confirmation of benefits will come with regulatory approval and subsequent real-world evidence.
Evidence for orforglipron's efficacy and safety is primarily derived from ongoing Phase 2 and Phase 3 clinical trials. These studies are designed to assess its effectiveness in reducing body weight and improving glycemic control in diverse populations.
* **Phase 2 Trials:** Early-phase studies, such as a published phase 2 trial (journal articles like New England Journal of Medicine), have demonstrated significant dose-dependent weight loss in participants with obesity or overweight, with or without type 2 diabetes. For example, participants receiving certain doses of orforglipron experienced substantial percentage body weight reductions over a period of 26 weeks, compared to placebo. These trials have also shown positive effects on glycemic parameters like HbA1c in individuals with type 2 diabetes.
* **Phase 3 Trials:** Large-scale Phase 3 trials are currently underway globally to further evaluate orforglipron against placebo and/or active comparators for long-term weight management and impact on cardiovascular outcomes. These trials involve thousands of participants and are critical for gathering comprehensive safety and efficacy data required for regulatory submissions (clinical trial registries such as ClinicalTrials.gov).
* **Mechanism Confirmation:** Independent research and in vitro studies have confirmed orforglipron's role as a potent and selective GLP-1 receptor agonist, providing a strong basis for its observed pharmacological effects (PubChem, chemical and biological research journals).
The collective evidence from these trials aims to establish orforglipron’s therapeutic profile, including its effectiveness, durability of effect, and safety compared to existing standards of care. Long-term data, particularly concerning cardiovascular safety, is still being collected and analyzed.
Like all medications, orforglipron can cause side effects, although not everyone experiences them. The most common side effects observed in clinical trials are generally gastrointestinal in nature, consistent with other GLP-1 receptor agonists.
Commonly reported side effects include:
* Nausea
* Diarrhea
* Vomiting
* Constipation
* Abdominal pain
These gastrointestinal side effects are often mild to moderate in severity and tend to be more pronounced during the initial weeks of treatment, gradually decreasing over time as the body adjusts (clinical trial reports, manufacturer data). Strategies such as gradual dose escalation are often employed to mitigate these effects.
Less common, but more serious, potential side effects observed with the GLP-1 receptor agonist class include:
* Pancreatitis: Inflammation of the pancreas. Patients should report severe, persistent abdominal pain.
* Gallbladder disease: Including gallstones or cholecystitis.
* Kidney problems: Worsening of kidney function, especially in patients with pre-existing kidney impairment or those experiencing severe gastrointestinal side effects leading to dehydration.
* Hypoglycemia: Low blood sugar, particularly when used in combination with other glucose-lowering medications like sulfonylureas or insulin.
Patients should discuss any side effects they experience with their clinician. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several important warnings and precautions are associated with the use of orforglipron, based on its mechanism of action and the known profile of the GLP-1 receptor agonist class. These are critical for patient safety and appropriate use.
* **Risk of Thyroid C-cell Tumors:** In rodent studies, GLP-1 receptor agonists have caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas). It is not known whether orforglipron causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Orforglipron is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (FDA Prescribing Information for approved GLP-1RAs).
* **Pancreatitis:** Acute pancreatitis has been reported in patients treated with GLP-1 receptor agonists. Patients should be monitored for signs and symptoms of pancreatitis, such as severe abdominal pain that may radiate to the back and may or may not be accompanied by vomiting. If pancreatitis is suspected, orforglipron should be discontinued immediately (FDA Prescribing Information for approved GLP-1RAs).
* **Gallbladder Disease:** Serious adverse reactions including cholelithiasis or cholecystitis have occurred with GLP-1 receptor agonists. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated (FDA Prescribing Information for approved GLP-1RAs).
* **Hypoglycemia:** The risk of hypoglycemia is increased when orforglipron is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin. A dose reduction of the insulin secretagogue or insulin may be necessary when initiating orforglipron (FDA Prescribing Information for approved GLP-1RAs).
* **Acute Kidney Injury:** There have been reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events were reported in patients without known underlying renal disease but in patients who experienced nausea, vomiting, or diarrhea leading to volume depletion. Patients should be monitored for renal function. Ensure adequate fluid intake (FDA Prescribing Information for approved GLP-1RAs).
* **Hypersensitivity Reactions:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinuing orforglipron and initiating appropriate medical treatment is recommended (FDA Prescribing Information for approved GLP-1RAs).
* **Acute Gastrointestinal Disease:** Due to potential for severe gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea), orforglipron has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended for use in these patients (manufacturer communications).
Patients should engage in open communication with their healthcare provider about their medical history and any concerns they may have. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Orforglipron has specific contraindications, meaning situations where the medication should not be used due to a high risk of adverse outcomes. These are derived from the known safety profile of GLP-1 receptor agonists.
* **Personal or Family History of Medullary Thyroid Carcinoma (MTC):** Orforglipron is contraindicated in patients with a personal or family history of MTC due to the observed risk of thyroid C-cell tumors in rodent studies with GLP-1 receptor agonists (FDA Prescribing Information for approved GLP-1RAs).
* **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2):** Patients with MEN 2 are also contraindicated due to the increased risk of MTC associated with this syndrome (FDA Prescribing Information for approved GLP-1RAs).
* **Prior Serious Hypersensitivity Reaction:** Individuals who have experienced a severe allergic reaction (e.g., anaphylaxis or angioedema) to orforglipron or any of its excipients should not use the medication (standard pharmaceutical practice for drug contraindications).
* **Pregnancy and Breastfeeding:** Orforglipron's safety in pregnant or breastfeeding women has not been established. Based on animal studies with other GLP-1 receptor agonists showing potential risks, and in the absence of human data, it is generally contraindicated during pregnancy and breastfeeding (standard regulatory guidance for investigational drugs, FDA Prescribing Information for approved GLP-1RAs).
These contraindications are established to protect patient safety. Always ensure your clinician is aware of your full medical history before considering any new medication. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While specific drug interaction studies for orforglipron are ongoing, based on its mechanism of action and the known interactions of the GLP-1 receptor agonist class, several considerations apply when combining it with other medications.
* **Insulin Secretagogues (e.g., Sulfonylureas) and Insulin:** Concomitant use with insulin or an insulin secretagogue significantly increases the risk of hypoglycemia. If co-administered, a dose reduction of the insulin secretagogue or insulin may be required, and blood glucose monitoring should be intensified (FDA Prescribing Information for approved GLP-1RAs).
* **Oral Medications with Narrow Therapeutic Index:** Because orforglipron delays gastric emptying, it has the potential to affect the absorption of orally administered medications, particularly those that require rapid gastrointestinal absorption or have a narrow therapeutic index (manufacturer product information for GLP-1RAs). Examples might include immunosuppressants like cyclosporine or certain anticoagulants. Careful monitoring and potential dose adjustments may be necessary.
* **Other GLP-1 Receptor Agonists:** Combining orforglipron with other GLP-1 receptor agonists is generally not recommended as it carries an increased risk of additive side effects (especially gastrointestinal) without clear evidence of additional benefit. Such combinations are not typically studied in clinical trials and would be considered off-label (standard medical practice).
* **Medications that Affect Gastric Emptying:** Co-administration with medications that also delay gastric emptying (e.g., anticholinergic drugs, opioids) could potentially exacerbate gastrointestinal side effects. Monitoring for increased nausea, vomiting, or other digestive issues would be essential (general pharmacokinetic principles).
Always inform your healthcare provider about all medications, supplements, and herbal products you are currently taking to avoid potential interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Orforglipron is designed for once-daily oral administration. Based on its pharmacokinetic profile, including a half-life of approximately 29 hours (manufacturer data via clinical trial reports), it can be taken consistently at any time of day, with or without food. The key is to maintain a regular schedule to ensure consistent drug levels and therapeutic effects.
* **Consistent Daily Administration:** It is generally recommended to take orforglipron at roughly the same time each day to establish a routine and minimize variability in drug exposure (general pharmaceutical advice).
* **With or Without Food:** Current data suggest that orforglipron can be taken independently of meals. This flexibility can improve convenience for patients and adherence to therapy (manufacturer communications). However, individual patient experience may vary, and some may find it preferable to take it with a meal if gastrointestinal side effects occur.
* **Morning Administration:** While not strictly required, taking it in the morning is often practical for once-daily medications, making it easier to remember. Nevertheless, evening administration is also acceptable if preferred.
Patients should follow the specific dosing instructions provided by their prescribing clinician and the manufacturer's eventual product labeling.
Source for this section: Sources for When should you take Orforglipron?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Orforglipron?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
Frequently asked questions about Orforglipron
Orforglipron is a glp1. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Orforglipron is commonly discussed in the context of supporting weight-loss and blood-sugar. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Orforglipron, it is typically taken in the morning and its approximate half-life is 29 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Orforglipron carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Orforglipron comes from the rest of the stack: other supplements, prescription medicines, hormone therapy and peptides. Because Orforglipron is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 29 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Orforglipron with no sign-up.
There is no single answer for Orforglipron plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Orforglipron with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 29 hours, once-daily dosing is the usual pattern for Orforglipron. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 29 hours, a single missed dose of Orforglipron usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Orforglipron the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Orforglipron?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment(opens PubMed in a new tab)N Engl J Med · 2025 · PMID 40960239 · https://pubmed.ncbi.nlm.nih.gov/40960239/
- 2.Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes(opens PubMed in a new tab)N Engl J Med · 2025 · PMID 40544435 · https://pubmed.ncbi.nlm.nih.gov/40544435/
- 3.Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity(opens PubMed in a new tab)N Engl J Med · 2023 · PMID 37351564 · https://pubmed.ncbi.nlm.nih.gov/37351564/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 137319706(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/137319706
Verify at
Publisher search links for Orforglipron. These are places to check the information — they are not citations, so they are not numbered.
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Clinical practice guidelines (PubMed)(publisher search, opens in a new tab)National Library of Medicine · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Orforglipron?
Plain-text summary, safe to quote verbatim:
Orforglipron is an investigational non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed for the treatment of obesity and type 2 diabetes. Research on Orforglipron focuses on weight loss and blood sugar control. It is typically taken in the morning. The reported plasma half-life is about 29 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/orforglipron
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Orforglipron — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/orforglipron
What compounds are similar to Orforglipron?
Others in the glp1 category or studied for the same goals.
Which goals is Orforglipron used for?
Other compounds studied for the same benefits as Orforglipron.
Continue exploring
See every compound DoseRoutine catalogs for these goals.